alamarbio.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $248.57MM
Alamar Biosciences is a biotechnology company that is striving to develop a precision proteomics platform that is used in protein biomarker detection. Their flagship technology platform is called NULISA (Nanoparticle Uninhibited Luminescent Immunoassay), and it aims to help researchers detect protein biomarkers down to attomolar concentrations, or extremely small amounts. Alamar Biosciences seeks to use the NULISA platform to increase the speed of development for new diagnostic tests that can detect diseases early and improve treatment options. Alamar Biosciences founded in 2018 and headquartered in Fremont, CA.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Alamar Biosciences.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.